ArticleCell biochemistry and biophysics2025
TUFT1 Modulates Cell Proliferation, Migration, Invasion, Stemness and EGFR Signaling in Cervical Cancer through Interacting with and Targeting ATF1.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a frequently-occurring gynecologic health problem posing a great threat to women. Tuftelin1 (TUFT1), an acidic protein possessing secretory capacity, has been reported to drive cisplatin resistance in cervical cancer cells. Accordingly, the current study is intended to figure out the specific impacts of TUFT1 on the aggressive behaviors of cervical cancer cells and make an in-depth study into the related regulatory mechanism. Firstly, analysis of TUFT1 expression in cervical cancer cells was performed by RT-qPCR and Western blotting. Cervical cancer cell proliferation was estimated via CCK-8 and colony formation assays. Wound healing, transwell as well as sphere formation assays were used to appraise cell migration, invasion, and stemness, respectively. Western blotting examined the expressions of metastasis- and stemness-associated factors and RT-qPCR also tested the expressions of stemness-associated factors. Co-IP assay was used to verify the binding between TUFT1 and activating transcription factor 1 (ATF1). Subsequent ATF1 expression was examined by RT-qPCR and Western blotting after TUFT1 was silenced. After co-transfected with TUFT1 interference and ATF1 overexpression plasmids, aforementioned functional experiments were conducted again. Western blotting also analyzed the expressions of epidermal growth factor receptor (EGFR) signaling-associated proteins. The experimental data determined that TUFT1 expression was fortified in cervical cancer cells and TUFT1 absence diminished cervical cancer cell proliferation, migration, invasion, and stemness. Besides, TUFT1 bond to ATF1 and positively modulated ATF1 expression. Moreover, ATF1 elevation countervailed the impacts of TUFT1 insufficiency on the proliferation, migration, invasion, stemness as well as EGFR signaling in cervical cancer cells. Anyway, TUFT1 might interact with ATF1 to elicit pro-proliferation, pro-metastasis, and pro-stemness properties and inactivate EGFR signaling in cervical cancer, supporting that TUFT1 might be valued as a potential hallmark for cervical cancer.
Indexed as
Identifiers
39948288What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.